Anokion

Anokion is a clinical-stage biotech pioneering a platform for antigen-specific tolerance induction to treat autoimmune diseases. Its core technology leverages the liver's natural immune tolerance pathways to re-educate the immune system to ignore specific self-antigens, offering a potentially curative and safer alternative to broad immunosuppressants. The company is advancing a pipeline of programs for celiac disease and multiple sclerosis, backed by experienced leadership and venture capital investors. As a private entity, its success hinges on clinical validation, platform expansion, and future strategic partnerships or financing.

Kön platform: Leverages the liver's natural immune tolerance pathways to deliver disease-specific antigens, generating antigen-specific regulatory T cells to restore immune tolerance without broad immunosuppression.

Anokion competes in the emerging field of antigen-specific tolerance, alongside companies like Immunic, Selecta Biosciences (now Sio Gene Therapies), and AnTolRx. It also faces indirect competition from all major pharmaceutical companies with broad immunosuppressants. Its key differentiator is the liver-targeting approach, which aims for a more natural and potentially durable form of tolerance.